Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds




Scilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds

PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common stock (the “Common Stock”) having an exercise of $38.50 per share and issued in April 2024 (the “April 2024 Warrants”) and (ii) 475,824 shares of Common Stock having an exercise price of $22.72 per share and issued in December 2024 (together with the April 2024 Warrants, the “Existing Warrants”) at a reduced exercise price of $22.51 per share. The aggregate gross proceeds from the exercise of the Existing Warrants were approximately $20.3 million, before deducting placement agent fees and other offering expenses payable by the Company.

Rodman & Renshaw LLC and StockBlock Securities LLC acted as the exclusive placement agents for the offering (the “Offering”).

In consideration for the immediate exercise of the Existing Warrants for cash, the Company issued to the holder of the Existing Warrants a new unregistered warrant to purchase up to an aggregate of 1,356,594 shares of Common Stock at an exercise price of $29.00 per share (the “New Warrant”). The New Warrant is exercisable immediately upon issuance and has a term of five years from the date of issuance.

The Company expects to use the net proceeds from the Offering for working capital and general corporate purposes.

The New Warrant described above was offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of Common Stock issuable upon exercise of the New Warrant, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the New Warrant issued in the private placement and the shares of Common Stock underlying the New Warrant may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of Common Stock issuable upon the exercise of the New Warrant.

This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.   

For more information on Scilex Holding Company, refer to www.scilexholding.com.

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com.

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
info@scilexholding.com     

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the anticipated use of proceeds from the Offering, future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, market and other conditions, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

UPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90%




UPDATED: PetVivo AI, Inc. Launches AI Platform Reducing Veterinary Client Acquisition Costs by 50-90%

Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market

Important Disclaimer: This updated press release replaces and supersedes the version issued earlier this morning, which should be disregarded due to inaccurate or incomplete information.

MINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) — PetVivo AI, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo Animal Health, Inc., an emerging biomedical device company focused on commercializing groundbreaking medical products and therapeutics for horses and companion animals, today announced the launch of PetVivo.ai. PetVivo.ai is a new artificial intelligence platform that has demonstrated in beta testing to deliver a customer acquisition cost of $42.53—an approximate 50–90% reduction compared to the $80–$400 typically spent by veterinary practices. The platform generates qualified leads for $3 per pet parent (versus $15–$45 through traditional digital advertising) and uses automated AI engagement to convert these leads into paying customers.

This launch represents a significant evolution for PetVivo Holdings as the company augments its existing product portfolio with a scalable, AI-driven Software-as-a-Service (SaaS) platform. PetVivo.ai complements the Company’s medical device offerings by introducing recurring revenue, advanced digital capabilities, and a high-margin business model—delivering 80–90% gross margins with the potential for substantial long-term scalability.

The Problem

Although the pet care industry now exceeds $150 billion annually, veterinary practices face a widening gap in how they reach today’s pet owners. Gen Z and Millennial pet parents account for 57% of all pet owners and expect modern digital experiences, yet many practices still depend on outdated marketing methods such as TV advertising and direct mail.

“Veterinary practices spend $80–$400 per new client depending on their marketing approach,” said John Lai, Chief Executive Officer. “Our AI generates qualified leads at just $3 each and converts them automatically. In our beta program, the median practice acquired 47 new clients over six months at a blended customer acquisition cost of $42.53—achieving approximately a 50–90% savings without the need for promotional discounting.”

The Solution

PetVivo.ai solves this problem through a suite of nine specialized AI agents operating continuously: Client Discovery, Campaign Manager, Engagement, Analytics, Content Creation, Reputation, Compliance, ROI Optimization, and Practice Integration. Together, these agents connect veterinary practices with millions of engaged pet parents through a two-sided ecosystem, while also giving veterinarians a valuable tool to support diagnosis and treatment decisions.

Industry-Leading Economics

The platform’s economics were validated in a 50-practice beta program:

• Lead Generation: $3 per qualified pet parent (vs. $15–$45 traditional)
• Customer Acquisition Cost: $42.53 blended CAC (vs. $80–$400 typical)
• Beta Results: 47 new clients median over 6 months (range: 12–124)
• Pricing: $1,999/month for the Professional tier
• LTV/CAC Ratio: 25:1 (best-in-class)
• Payback Period: 1 month
• Gross Margins: 80–90%

Market Opportunity

PetVivo.ai serves a large and under-digitized market consisting of 30,000 U.S. veterinary practices and more than 100,000 practices worldwide. With increasing demand for modern, AI-driven client engagement solutions—and limited competition in this category—the platform is positioned for broad adoption across both independent clinics and multi-location hospital groups. The size of the addressable market and the recurring nature of SaaS subscriptions provide a substantial runway for long-term growth and expansion.

The Catalyst

The launch serves as a major catalyst for re-valuing the company as it transitions from traditional medical device revenue multiples (1–2x revenue) to AI SaaS multiples (15–30x revenue). Comparable companies such as Salesforce, HubSpot, Veeva Systems, and C3.ai trade at median multiples near 15x, suggesting potential 5–10x valuation upside as PetVivo.ai scales.

“We are expanding our capabilities beyond our established medical device operations by introducing a powerful AI SaaS platform,” added Mr. Lai. “As we continue to scale both sides of the business, we believe this positions the Company for broader recognition of the full value we are building.”

Competitive Advantages

PetVivo.ai holds a first-mover advantage with no direct AI competitors, strong two-sided network effects, and existing relationships with 1,200 veterinary clinic distributors (with plans to target in excess of an additional 7,000). Deep integrations with practice management systems further accelerate adoption and reduce onboarding friction.

Commercial Launch

Following successful beta testing, PetVivo.ai is now fully commercial with open sign-ups at www.petvivo.ai, a 14-day free trial, three pricing tiers, and both direct-sales and self-service onboarding.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with its wholly owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twelve patents and six trade secrets protect the Company’s biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG^® with OsteoCushion^® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP^®, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.

Company Contact
John Lai, CEO
PetVivo Holdings, Inc.
Email Contact
Tel (952) 405-6216

Forward-Looking commercial Statements

The foregoing information regarding PetVivo Holdings, Inc. (the “Company”) may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 47_2025

IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 47 – 2025

Attachment

• EN_IPSEN – Buy-back programme – Art 5 of MAR – Week 47_2025

Health Care Resource Centers Appoints Dr. Katherine Krauskopf as Regional Medical Director in Western Massachusetts




Health Care Resource Centers Appoints Dr. Katherine Krauskopf as Regional Medical Director in Western Massachusetts

To lead addiction treatment programs across Greenfield, Westfield, Northampton, and Chicopee

CHICOPEE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) — Health Care Resource Centers (HCRC), a BayMark Health Services company, has appointed Katherine Krauskopf, MD, MPH, FASAM, as Regional Medical Director overseeing programs in Greenfield, Westfield, Northampton, and Chicopee.

Dr. Krauskopf brings more than eight years of experience in addiction medicine and a strong foundation in primary care. She earned her Doctor of Medicine and Master of Public Health degrees from the Icahn School of Medicine at Mount Sinai in New York and is a Fellow of the American Society of Addiction Medicine.

“Addiction medicine allows me to practice evidence-based care while seeing real, positive change,” said Dr. Krauskopf. “At HCRC, we’re treating the whole person and helping them rebuild their lives.”

HCRC provides comprehensive treatment for opioid use disorder through medication-assisted treatment and supportive counseling. With updated methadone regulations, Dr. Krauskopf aims to expand flexible, personalized care focused on long-term wellness.

With Dr. Krauskopf’s appointment, HCRC strengthens its commitment to compassionate, evidence-based care that supports lasting recovery. Regional Director of Operations Michael Brassard noted that her leadership reinforces HCRC’s mission to treat the whole person—mind, body, and spirit—for meaningful, long-term recovery.

To learn more about HCRC and the recovery services it provides, visit HCRCenters.com.

About Health Care Resource Centers (HCRC)
Health Care Resource Centers, a BayMark Health Services company, provides outpatient medication-assisted treatment and counseling for individuals living with opioid use disorder. With multiple locations throughout New England, HCRC delivers compassionate, evidence-based care that helps patients build a path toward recovery and wellness.

CONTACT: Contact: media@baymark.com 

Health Care Resource Centers Appoints Dr. Katherine Krauskopf as Regional Medical Director in Western Massachusetts




Health Care Resource Centers Appoints Dr. Katherine Krauskopf as Regional Medical Director in Western Massachusetts

To lead addiction treatment programs across Greenfield, Westfield, Northampton, and Chicopee

CHICOPEE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) — Health Care Resource Centers (HCRC), a BayMark Health Services company, has appointed Katherine Krauskopf, MD, MPH, FASAM, as Regional Medical Director overseeing programs in Greenfield, Westfield, Northampton, and Chicopee.

Dr. Krauskopf brings more than eight years of experience in addiction medicine and a strong foundation in primary care. She earned her Doctor of Medicine and Master of Public Health degrees from the Icahn School of Medicine at Mount Sinai in New York and is a Fellow of the American Society of Addiction Medicine.

“Addiction medicine allows me to practice evidence-based care while seeing real, positive change,” said Dr. Krauskopf. “At HCRC, we’re treating the whole person and helping them rebuild their lives.”

HCRC provides comprehensive treatment for opioid use disorder through medication-assisted treatment and supportive counseling. With updated methadone regulations, Dr. Krauskopf aims to expand flexible, personalized care focused on long-term wellness.

With Dr. Krauskopf’s appointment, HCRC strengthens its commitment to compassionate, evidence-based care that supports lasting recovery. Regional Director of Operations Michael Brassard noted that her leadership reinforces HCRC’s mission to treat the whole person—mind, body, and spirit—for meaningful, long-term recovery.

To learn more about HCRC and the recovery services it provides, visit HCRCenters.com.

About Health Care Resource Centers (HCRC)
Health Care Resource Centers, a BayMark Health Services company, provides outpatient medication-assisted treatment and counseling for individuals living with opioid use disorder. With multiple locations throughout New England, HCRC delivers compassionate, evidence-based care that helps patients build a path toward recovery and wellness.

CONTACT: Contact: media@baymark.com 

Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary




Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary

Pau Hana Plans Ambitious Expansion Roadmap and New Location Acquisitions in the Pipeline

MELBOURNE, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC:BLEG), a leader in innovative addiction treatment and harm reduction solutions, today announced that its newly acquired subsidiary, Pau Hana, posted strong third quarter revenues of just over one hundred and twenty-five thousand dollars ($125,000.00). Branded Legacy intends to aggressively scale this division throughout 2026 and beyond through a targeted roll-up strategy of additional high-performing locations. Each future acquisition will follow the Pau Hana blueprint: integrating established, cash-flow-positive kava bars into the portfolio to immediately layer on new streams of daily retail revenue while leveraging centralized sourcing, branding, and operational efficiencies to boost margins. This repeatable acquisition model is designed to drive exponential, compounding revenue growth, positioning Branded Legacy as a dominant consolidator in the multi-billion-dollar sober-social and functional beverage movement.

Branded Legacy, Inc. has strategically diversified its portfolio with the strategic acquisition of Pau Hana, marking its bold entry into the fast-growing kava and wellness lounge sector. This milestone acquisition instantly unlocked daily, recurring revenue streams from Pau Hana’s thriving retail operation in West Melbourne, Florida, a location that has consistently generated strong cash flow since its 2023 launch through premium kava sales, specialty mocktails, events, and merchandise. Unlike one-time product sales, Pau Hana delivers predictable, high-margin daily income from foot traffic, repeat clientele, and a loyal membership base, providing Branded Legacy with a stable new revenue pillar that significantly enhances overall financial performance and shareholder value.

As Pau Hana looks ahead to 2026, the team is channeling its explosive growth since opening in West Melbourne, Florida, in January 2023 into a bold expansion strategy designed to bring the island-inspired, alcohol-free relaxation revolution to new horizons. With a meticulously planned roadmap that includes opening three to five new locations across high-potential markets in Florida, targeting vibrant communities in and around Central Florida. The brand aims to scale its footprint by 150% within the year, capitalizing on the surging demand for wellness-focused social spaces. This organic growth will feature flagship venues that blend traditional kava rituals with modern amenities like expanded event programming and pet-friendly lounges, all while maintaining the core commitment to noble kava varieties that deliver anxiety-reducing calm and euphoric vibes without the regrets of traditional nightlife.

Branded Legacy intends to aggressively scale its kava bar division throughout 2026 and beyond through a targeted roll-up strategy of additional high-performing locations. Each future acquisition will follow the Pau Hana blueprint: integrating established, cash-flow-positive kava bars into the portfolio to immediately layer on new streams of daily retail revenue while leveraging centralized sourcing, branding, and operational efficiencies to boost margins. This repeatable acquisition model is designed to drive exponential, compounding revenue growth, positioning Branded Legacy as a dominant consolidator in the multi-billion-dollar sober-social and functional beverage movement.

Branded Legacy recognized the benefits of Kava and how Kava’s appeal lies largely in its well-documented calming and mood-enhancing effects, which come primarily from active compounds called kavalactones. In recent years, kava bars have rapidly emerged as a popular social destination across the United States and beyond, evolving from a traditional Pacific Island ritual into a modern wellness and nightlife alternative. Cities like South Florida, Southern California, Colorado, and North Carolina now host dozens of dedicated kava bars. Unlike traditional bars, kava venues promote a relaxed, alcohol-free environment where patrons gather to drink “shells” of the earthy, tongue-numbing beverage while playing games, listening to live music, or simply unwinding. The trend has been fueled by growing interest in natural alternatives to alcohol, especially among younger adults seeking social spaces that don’t revolve around drinking or late-night partying.

About Pau Hana.

Nestled at the vibrant intersection of U.S. Highway 192 and Wickham Road in West Melbourne, Florida, Pau Hana Kava Bar opened its doors in January 2023 as a welcoming haven for those seeking a mindful escape from the everyday hustle. Drawing inspiration from the Hawaiian phrase “Pau Hana,” which celebrates the sweet relief of the workday’s end, this pet-friendly spot embodies the spirit of community and relaxation in a sophisticated, alcohol-free environment. Founded with a passion for natural wellness, Pau Hana has quickly become a local favorite, offering a refreshing alternative to traditional bars where patrons can unwind without the haze of hangovers or regrets. Our commitment to quality shines through in every carefully crafted beverage, fostering connections among friends, families, and newcomers alike in a space designed for genuine, feel-good vibes. Please visit: https://pauhanakava.com/

Branded Legacy recently announced that it’s subsidiary BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone marks a significant step toward scalable production of its groundbreaking single-use device, designed to deliver rapid, consistent, and reliable therapeutics, including its flagship inhaled naloxone program.

About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BioLegacy is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.

About Pau Hana

Florida, Pau Hana Kava Bar opened its doors in January 2023 as a welcoming haven for those seeking a mindful escape from the everyday hustle. Drawing inspiration from the Hawaiian phrase “Pau Hana,” which celebrates the sweet relief of the workday’s end, this pet-friendly spot embodies the spirit of community and relaxation in a sophisticated, alcohol-free environment.

About Branded Legacy, Inc.

Branded Legacy, Inc. (OTC:BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges. For more information, visit www.brandedlegacy.com.

Investor Relations

Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

InvestorWire Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.




LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.

Proud to Support a Foundation for a World Free of Gender-Based Violence

Toronto, Ontario, Nov. 25, 2025 (GLOBE NEWSWIRE) — LifeLabs, Canada’s leading provider of medical diagnostic services, is proud to donate $10,000 to Guelph-Wellington Women in Crisis, a charitable social purpose organization that provides safety, support, information, and advocacy to women and gender-diverse people, and their children.  

November 25th is the International Day for the Elimination of Violence Against Women. Tragically, violence against women, gender-diverse people and girls remains one of the most prevalent and pervasive human rights violations in the world. Globally, almost one in three women has been subjected to physical assault at least once in their lives with incidents of intimate partner violence reported to police rising by 19 per cent between 2014 and 2022. In Ontario alone, the number of femicides in 2024 was a horrifying 62 individuals. This year, the day will focus on ending digital violence against women and girls, a form of violence that is increasing dramatically. 

In the face of these stark statistics, we are reminded of the strength of survivors of gender-based violence and the importance of working to end it. 

LifeLabs is proud to stand alongside survivors and is committed to doing our part to lay the foundation for a world that is free of gender-based violence. 

“On this International Day for the Elimination of Violence Against Women, LifeLabs joins the call to end gender-based violence,” said Charles Brown, CEO and President of LifeLabs. “We are inspired by the work being done by Women in Crisis and are proud to support their mission.” 

“We are deeply grateful to LifeLabs for their generous support. When corporations invest in local organizations, they help build stronger, healthier communities, both for their own employees and for the wider community of family, friends and neighbours. This partnership between LifeLabs and us will enhance support for those impacted by gender-based violence. This gift is an investment that will help ensure vital, often life-saving services, remain accessible to those who need them most,” said Sly Castaldi, Executive Director of Guelph-Wellington Women in Crisis. 

To survivors and to all those who work to build connection and care in the communities we serve, thank you. We are honoured to walk alongside you. 

For 24-hour anonymous support, you can reach the Women in Crisis Crisis Line at 519-836-5710 or 1-800-265-7233. If you are in an emergency situation, please call 9-1-1 (in Canada) for immediate services in your area. If you or someone you know is experiencing gender-based violence, consult the list of additional support services for people affected by gender-based violence. 

About LifeLabs 

Empowering healthier Canadians for over 60 years, LifeLabs was founded in Canada and remains dedicated to serving Canadian communities. As Canada’s leading provider of laboratory diagnostic information and digital health connectivity systems, LifeLabs enables patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. We support over 15 million patient visits annually and conduct over 140 million laboratory tests through leading-edge technologies and our 6,500 talented and dedicated employees located across Canada. We are a committed innovator in supporting Canadians to live healthier lives, operating Canada’s first commercial genetics lab and the country’s largest online patient portal, with more than 9 million Canadians receiving their results online. LifeLabs has been named one of Canada’s Best Employers (2021, 2022 and 2023) and Best Employers for Diversity (2022 and 2023) by Forbes and recognized for having an award-winning Mental Health Program from Benefits Canada. 

About Guelph-Wellington Women in Crisis 

Guelph-Wellington Women in Crisis is a feminist, community-based organization that is fiercely committed to safety, advocacy, education, and support for women and gender-diverse people impacted by gender-based violence (GBV). For nearly 50 years, we have been a leader in both prevention and intervention, helping survivors rebuild their lives while working to create lasting systemic change. Our Programs & Services include: 24-hour Crisis Line, emergency residential shelter at Marianne’s Place (28 beds), four counselling & support service programs in Guelph [Transitional and Housing Support, Family Court Support, Anti-Human Trafficking, Sexual Assault Centre] and Rural Women’s Support Program offices in Fergus, Mount Forest, Palmerston & Erin. 

Attachment

• LifeLabs and Guelph-Wellington Women in Crisis

CONTACT: Media Team
LifeLabs
media@lifelabs.com

Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary




Branded Legacy Announces Strong Revenues from Newly Acquired Pau Hana Subsidiary

Pau Hana Plans Ambitious Expansion Roadmap and New Location Acquisitions in the Pipeline

MELBOURNE, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC:BLEG), a leader in innovative addiction treatment and harm reduction solutions, today announced that its newly acquired subsidiary, Pau Hana, posted strong third quarter revenues of just over one hundred and twenty-five thousand dollars ($125,000.00). Branded Legacy intends to aggressively scale this division throughout 2026 and beyond through a targeted roll-up strategy of additional high-performing locations. Each future acquisition will follow the Pau Hana blueprint: integrating established, cash-flow-positive kava bars into the portfolio to immediately layer on new streams of daily retail revenue while leveraging centralized sourcing, branding, and operational efficiencies to boost margins. This repeatable acquisition model is designed to drive exponential, compounding revenue growth, positioning Branded Legacy as a dominant consolidator in the multi-billion-dollar sober-social and functional beverage movement.

Branded Legacy, Inc. has strategically diversified its portfolio with the strategic acquisition of Pau Hana, marking its bold entry into the fast-growing kava and wellness lounge sector. This milestone acquisition instantly unlocked daily, recurring revenue streams from Pau Hana’s thriving retail operation in West Melbourne, Florida, a location that has consistently generated strong cash flow since its 2023 launch through premium kava sales, specialty mocktails, events, and merchandise. Unlike one-time product sales, Pau Hana delivers predictable, high-margin daily income from foot traffic, repeat clientele, and a loyal membership base, providing Branded Legacy with a stable new revenue pillar that significantly enhances overall financial performance and shareholder value.

As Pau Hana looks ahead to 2026, the team is channeling its explosive growth since opening in West Melbourne, Florida, in January 2023 into a bold expansion strategy designed to bring the island-inspired, alcohol-free relaxation revolution to new horizons. With a meticulously planned roadmap that includes opening three to five new locations across high-potential markets in Florida, targeting vibrant communities in and around Central Florida. The brand aims to scale its footprint by 150% within the year, capitalizing on the surging demand for wellness-focused social spaces. This organic growth will feature flagship venues that blend traditional kava rituals with modern amenities like expanded event programming and pet-friendly lounges, all while maintaining the core commitment to noble kava varieties that deliver anxiety-reducing calm and euphoric vibes without the regrets of traditional nightlife.

Branded Legacy intends to aggressively scale its kava bar division throughout 2026 and beyond through a targeted roll-up strategy of additional high-performing locations. Each future acquisition will follow the Pau Hana blueprint: integrating established, cash-flow-positive kava bars into the portfolio to immediately layer on new streams of daily retail revenue while leveraging centralized sourcing, branding, and operational efficiencies to boost margins. This repeatable acquisition model is designed to drive exponential, compounding revenue growth, positioning Branded Legacy as a dominant consolidator in the multi-billion-dollar sober-social and functional beverage movement.

Branded Legacy recognized the benefits of Kava and how Kava’s appeal lies largely in its well-documented calming and mood-enhancing effects, which come primarily from active compounds called kavalactones. In recent years, kava bars have rapidly emerged as a popular social destination across the United States and beyond, evolving from a traditional Pacific Island ritual into a modern wellness and nightlife alternative. Cities like South Florida, Southern California, Colorado, and North Carolina now host dozens of dedicated kava bars. Unlike traditional bars, kava venues promote a relaxed, alcohol-free environment where patrons gather to drink “shells” of the earthy, tongue-numbing beverage while playing games, listening to live music, or simply unwinding. The trend has been fueled by growing interest in natural alternatives to alcohol, especially among younger adults seeking social spaces that don’t revolve around drinking or late-night partying.

About Pau Hana.

Nestled at the vibrant intersection of U.S. Highway 192 and Wickham Road in West Melbourne, Florida, Pau Hana Kava Bar opened its doors in January 2023 as a welcoming haven for those seeking a mindful escape from the everyday hustle. Drawing inspiration from the Hawaiian phrase “Pau Hana,” which celebrates the sweet relief of the workday’s end, this pet-friendly spot embodies the spirit of community and relaxation in a sophisticated, alcohol-free environment. Founded with a passion for natural wellness, Pau Hana has quickly become a local favorite, offering a refreshing alternative to traditional bars where patrons can unwind without the haze of hangovers or regrets. Our commitment to quality shines through in every carefully crafted beverage, fostering connections among friends, families, and newcomers alike in a space designed for genuine, feel-good vibes. Please visit: https://pauhanakava.com/

Branded Legacy recently announced that it’s subsidiary BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This milestone marks a significant step toward scalable production of its groundbreaking single-use device, designed to deliver rapid, consistent, and reliable therapeutics, including its flagship inhaled naloxone program.

About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group Inc. is a life sciences company dedicated to developing innovative therapies and devices addressing urgent global health challenges. With strategic partnerships at McMaster University and Stanford University, and a newly acquired GMP-compliant manufacturing facility, BioLegacy is positioned to deliver scalable, cost-effective solutions in areas of high unmet need.

About Pau Hana

Florida, Pau Hana Kava Bar opened its doors in January 2023 as a welcoming haven for those seeking a mindful escape from the everyday hustle. Drawing inspiration from the Hawaiian phrase “Pau Hana,” which celebrates the sweet relief of the workday’s end, this pet-friendly spot embodies the spirit of community and relaxation in a sophisticated, alcohol-free environment.

About Branded Legacy, Inc.

Branded Legacy, Inc. (OTC:BLEG) is a forward-thinking holdings company dedicated to pioneering solutions in addiction treatment and harm reduction. Through its subsidiary, BioLegacy Evaluative Group, and strategic collaborations with leading institutions like McMaster University and Stanford University, the company drives transformative research and innovation. With a state-of-the-art GMP manufacturing facility in Vancouver, Branded Legacy leverages advanced production capabilities to deliver cutting-edge products, positioning itself as a leader in addressing critical public health challenges. For more information, visit www.brandedlegacy.com.

Investor Relations

Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.

InvestorWire Contact:
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.




LifeLabs Donates $10,000 to Women in Crisis in Honour of the International Day for the Elimination of Violence Against Women and Girls.

Proud to Support a Foundation for a World Free of Gender-Based Violence

Toronto, Ontario, Nov. 25, 2025 (GLOBE NEWSWIRE) — LifeLabs, Canada’s leading provider of medical diagnostic services, is proud to donate $10,000 to Guelph-Wellington Women in Crisis, a charitable social purpose organization that provides safety, support, information, and advocacy to women and gender-diverse people, and their children.  

November 25th is the International Day for the Elimination of Violence Against Women. Tragically, violence against women, gender-diverse people and girls remains one of the most prevalent and pervasive human rights violations in the world. Globally, almost one in three women has been subjected to physical assault at least once in their lives with incidents of intimate partner violence reported to police rising by 19 per cent between 2014 and 2022. In Ontario alone, the number of femicides in 2024 was a horrifying 62 individuals. This year, the day will focus on ending digital violence against women and girls, a form of violence that is increasing dramatically. 

In the face of these stark statistics, we are reminded of the strength of survivors of gender-based violence and the importance of working to end it. 

LifeLabs is proud to stand alongside survivors and is committed to doing our part to lay the foundation for a world that is free of gender-based violence. 

“On this International Day for the Elimination of Violence Against Women, LifeLabs joins the call to end gender-based violence,” said Charles Brown, CEO and President of LifeLabs. “We are inspired by the work being done by Women in Crisis and are proud to support their mission.” 

“We are deeply grateful to LifeLabs for their generous support. When corporations invest in local organizations, they help build stronger, healthier communities, both for their own employees and for the wider community of family, friends and neighbours. This partnership between LifeLabs and us will enhance support for those impacted by gender-based violence. This gift is an investment that will help ensure vital, often life-saving services, remain accessible to those who need them most,” said Sly Castaldi, Executive Director of Guelph-Wellington Women in Crisis. 

To survivors and to all those who work to build connection and care in the communities we serve, thank you. We are honoured to walk alongside you. 

For 24-hour anonymous support, you can reach the Women in Crisis Crisis Line at 519-836-5710 or 1-800-265-7233. If you are in an emergency situation, please call 9-1-1 (in Canada) for immediate services in your area. If you or someone you know is experiencing gender-based violence, consult the list of additional support services for people affected by gender-based violence. 

About LifeLabs 

Empowering healthier Canadians for over 60 years, LifeLabs was founded in Canada and remains dedicated to serving Canadian communities. As Canada’s leading provider of laboratory diagnostic information and digital health connectivity systems, LifeLabs enables patients and healthcare practitioners to diagnose, treat, monitor, and prevent disease. We support over 15 million patient visits annually and conduct over 140 million laboratory tests through leading-edge technologies and our 6,500 talented and dedicated employees located across Canada. We are a committed innovator in supporting Canadians to live healthier lives, operating Canada’s first commercial genetics lab and the country’s largest online patient portal, with more than 9 million Canadians receiving their results online. LifeLabs has been named one of Canada’s Best Employers (2021, 2022 and 2023) and Best Employers for Diversity (2022 and 2023) by Forbes and recognized for having an award-winning Mental Health Program from Benefits Canada. 

About Guelph-Wellington Women in Crisis 

Guelph-Wellington Women in Crisis is a feminist, community-based organization that is fiercely committed to safety, advocacy, education, and support for women and gender-diverse people impacted by gender-based violence (GBV). For nearly 50 years, we have been a leader in both prevention and intervention, helping survivors rebuild their lives while working to create lasting systemic change. Our Programs & Services include: 24-hour Crisis Line, emergency residential shelter at Marianne’s Place (28 beds), four counselling & support service programs in Guelph [Transitional and Housing Support, Family Court Support, Anti-Human Trafficking, Sexual Assault Centre] and Rural Women’s Support Program offices in Fergus, Mount Forest, Palmerston & Erin. 

Attachment

• LifeLabs and Guelph-Wellington Women in Crisis

CONTACT: Media Team
LifeLabs
media@lifelabs.com